Clin Exp Vaccine Res.  2014 Jul;3(2):149-154. 10.7774/cevr.2014.3.2.149.

Vaccine strategies utilizing C-type lectin receptors on dendritic cells in vivo

Affiliations
  • 1Laboratory of Immunology, Severance Biomedical Science Institute, Brain 21 PLUS project for Medical Science, Yonsei University College of Medicine, Seoul, Korea. ChaeGyu@yuhs.ac

Abstract

Dendritic cells (DCs) are professional antigen-presenting cells capable of initiating and regulating innate and adaptive immunity. The development of effective ways to produce a large number of DCs in laboratories made the use of DCs available in various vaccine approaches. Compared to conventional vaccines, focused on protective antibody responses, DC vaccines emphasize protective T cell immunity but might elicit strong antibody responses as well. In addition, the recent discoveries of functionally distinct DC subsets in various organs and tissues are likely to increase the potential of exploiting DCs in vaccines and immunotherapy. Vaccines composed of DCs generated ex vivo, pulsed with antigens, and matured prior to being re-infused to the body have been widely tried clinically but resulted in limited success due to various obstacles. In this review, new approaches that protein vaccines are selectively targeted to the endocytic C-type lectin receptors on surface of DCs in vivo are discussed.

Keyword

Antigen receptor; C-type lectins; Dendritic cells; Monoclonal antibody

MeSH Terms

Adaptive Immunity
Antibody Formation
Antigen-Presenting Cells
Dendritic Cells*
Immunotherapy
Lectins, C-Type*
Receptors, Antigen
Vaccines
Lectins, C-Type
Receptors, Antigen
Vaccines

Figure

  • Fig. 1 Analyses of human immunodeficiency virus Gag proteins expressed from mammalian CHO cells. (A) Soluble, FLAG-tagged Gag p41 and p24 proteins were produced into culture media from the stably transfected CHO cells, followed by anti-FLAG affinity purification. Left panel: Five micrograms each of purified p41 and p24 was subjected to sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis with/without (+/-) treatment of β-mercaptoethanol (BME) and boiling at 100℃ for 5 minutes (Boiling). After electrophoresis, the gel was visualized with Coomassie blue stain. Aggregates on the border between stacking and resolving gels and on the bottom of loading wells are detected from the purified p41 without BME & Boiling. Right panel: Zero point five microgram each of purified p41 and p24 was subjected to SDS-polyacrylamide gel electrophoresis with/without BME & Boiling. After electrophoresis, the gel was transferred onto polyvinylidene difluoride (PVDF) membrane, blotted with anti-Gag antibody, and visualized with chemiluminescent reagent. Aggregates with high molecular weight are detected from the purified p41 without BME & Boiling. (B) Culture supernatants from stably transfected CHO cells expressing soluble, FLAG-tagged Gag p41 and p24 proteins were analyzed. Five microliters each of cell culture supernatants was subjected to SDS-polyacrylamide gel electrophoresis with/without BME & Boiling. After electrophoresis, the gel was transferred onto PVDF membrane, blotted with anti-Gag antibody, and visualized with chemiluminescent reagent. Aggregates with high molecular weight are detected from the cell culture supernatant of p41 without BME & Boiling.


Cited by  2 articles

TCF4-Targeting miR-124 is Differentially Expressed amongst Dendritic Cell Subsets
Sun Murray Han, Hye Young Na, Onju Ham, Wanho Choi, Moah Sohn, Seul Hye Ryu, Hyunju In, Ki-Chul Hwang, Chae Gyu Park
Immune Netw. 2016;16(1):61-74.    doi: 10.4110/in.2016.16.1.61.

Extended Culture of Bone Marrow with Granulocyte Macrophage-Colony Stimulating Factor Generates Immunosuppressive Cells
Hye Young Na, Moah Sohn, Seul Hye Ryu, Wanho Choi, Hyunju In, Hyun Soo Shin, Chae Gyu Park
Immune Netw. 2018;18(2):.    doi: 10.4110/in.2018.18.e16.


Reference

1. Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science. Immunity. 2008; 29:319–324.
Article
2. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. 2012; 30:1–22.
Article
3. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998; 392:245–252.
Article
4. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell. 2001; 106:271–274.
Article
5. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007; 449:419–426.
Article
6. Trumpfheller C, Longhi MP, Caskey M, et al. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med. 2012; 271:183–192.
Article
7. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003; 21:685–711.
Article
8. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363:411–422.
Article
9. Sabado RL, Bhardwaj N. Dendritic cell immunotherapy. Ann N Y Acad Sci. 2013; 1284:31–45.
Article
10. Kraal G, Breel M, Janse M, Bruin G. Langerhans' cells, veiled cells, and interdigitating cells in the mouse recognized by a monoclonal antibody. J Exp Med. 1986; 163:981–997.
Article
11. Jiang W, Swiggard WJ, Heufler C, et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature. 1995; 375:151–155.
Article
12. Mahnke K, Guo M, Lee S, et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol. 2000; 151:673–684.
Article
13. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med. 2002; 196:1627–1638.
Article
14. Lahoud MH, Ahmet F, Zhang JG, et al. DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc Natl Acad Sci U S A. 2012; 109:16270–16275.
Article
15. Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001; 194:769–779.
Article
16. Hawiger D, Masilamani RF, Bettelli E, Kuchroo VK, Nussenzweig MC. Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity. 2004; 20:695–705.
Article
17. Bonifaz LC, Bonnyay DP, Charalambous A, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med. 2004; 199:815–824.
Article
18. Trumpfheller C, Finke JS, Lopez CB, et al. Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med. 2006; 203:607–617.
Article
19. Bozzacco L, Trumpfheller C, Siegal FP, et al. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A. 2007; 104:1289–1294.
Article
20. Do Y, Koh H, Park CG, et al. Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague. Eur J Immunol. 2010; 40:2791–2796.
Article
21. Trumpfheller C, Caskey M, Nchinda G, et al. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci U S A. 2008; 105:2574–2579.
Article
22. Longhi MP, Trumpfheller C, Idoyaga J, et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med. 2009; 206:1589–1602.
Article
23. Caskey M, Lefebvre F, Filali-Mouhim A, et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med. 2011; 208:2357–2366.
Article
24. Guo M, Gong S, Maric S, et al. A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells. Hum Immunol. 2000; 61:729–738.
Article
25. Kato M, McDonald KJ, Khan S, et al. Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. Int Immunol. 2006; 18:857–869.
Article
26. Cheong C, Choi JH, Vitale L, et al. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood. 2010; 116:3828–3838.
Article
27. Park CG, Rodriguez A, Ueta H, et al. Generation of anti-human DEC205/CD205 monoclonal antibodies that recognize epitopes conserved in different mammals. J Immunol Methods. 2012; 377:15–22.
Article
28. Dudziak D, Kamphorst AO, Heidkamp GF, et al. Differential antigen processing by dendritic cell subsets in vivo. Science. 2007; 315:107–111.
Article
29. Cheong C, Matos I, Choi JH, et al. Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell. 2010; 143:416–429.
Article
30. Cheong C, Matos I, Choi JH, et al. New monoclonal anti-mouse DC-SIGN antibodies reactive with acetone-fixed cells. J Immunol Methods. 2010; 360:66–75.
Article
31. Gardner JM, Metzger TC, McMahon EJ, et al. Extrathymic Aire-expressing cells are a distinct bone marrow-derived population that induce functional inactivation of CD4(+) T cells. Immunity. 2013; 39:560–572.
Article
32. Flynn BJ, Kastenmuller K, Wille-Reece U, et al. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A. 2011; 108:7131–7136.
Article
Full Text Links
  • CEVR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr